Advanced Enzyme Technologies Ltd.
CIN: L24200MH1989PLC051018
Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India
Tel: +91-22-4170 3200, Fax: +91-22-2583 5159
Email: info@advancedenzymes.com, www.advancedenzymes.com

August 08, 2026

BSE Limited
P. J. Towers,
Dalal Street,
Mumbai- 400 001

Scrip Code-540025

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (E) Mumbai- 400 051

Trading Symbol-ADVENZYMES

Subject: Earnings Presentation
Ref: ISIN: INE837H01020

Dear Sir/Madam,

Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is the Earnings Presentation for the quarter ended June 30, 2026.

This is for your information and for public at large.

Thanking you,
Yours faithfully,
For Advanced Enzyme Technologies Limited

SANJAY PRAKASH BASANTANI
Digitally signed by SANJAY PRAKASH BASANTANI
Date: 2026.08.08 16:04:11 +05'30'

Sanjay Basantani
Company Secretary and Head – Legal

Encl.: As above

advanced enzymes
Where ENZYME is Life

Advanced Enzyme Technologies Limited

Earnings Presentation
August 2026

Safe Harbour Statement

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words "believe," "expect," "anticipate," "intend," "estimate," "outlook," "will," "may," "continue," "should" and similar expressions identify forward-looking statements.

Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; liquidity, capital resources and capital expenditures; economic outlook and industry trends; developments of the Company's markets; the impact of regulatory initiatives; and the strength of competitors. The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and maybe beyond our control. Such risks, uncertainties, contingencies and other important factors could cause the actual results of the Company or the industry to differ materially from those results expressed or implied in this presentation by such forward-looking statements.

The information, opinions and forward-looking statements contained in this presentation speak only as at the date of this presentation and are subject to change without notice. The Company and its respective agents, employees or advisors do not intend to, and expressly disclaim any duty, undertaking or obligation to, make or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward-looking statements contained in this presentation to reflect any change in events, conditions or circumstances beyond what is required by applicable law or applicable stock exchange rules and regulations.

By viewing this presentation, you acknowledge and agree to be bound by the foregoing limitations and restrictions.

TABLE OF CONTENTS

Results Summary – Q1 FY27 (Consolidated) Y-o-Y

Revenue (₹ mn)



EBITDA (₹ mn)



PAT (₹ mn)



Revenue grew by 2% on y-o-y basis to ₹ 1,898 million in Q1 FY27 from ₹ 1,859 million in Q1 FY26

EBITDA de-grew by 10% to ₹ 510 million in Q1 FY27 as against ₹ 564 million in Q1 FY26 on y-o-y basis

PAT decreased to ₹ 386 million in Q1 FY27 from ₹ 404 million in Q1 FY26, decline of 5% on y-o-y basis

EBITDA margin and PAT margin during Q1 FY27 stands at 27% and 20% respectively

Notes:
1. On Consolidated Basis
2. PAT is before minority
3. Ind AS adjustments are carried out on account of commission, discount. And provision for sales return

Results Summary – Q1 FY27 (Consolidated) Q-o-Q

Revenue (₹ mn)



EBITDA (₹ mn)



PAT (₹ mn)



Revenue de-grew by 7% on q-o-q basis to ₹ 1,898 million in Q1 FY27 from ₹ 2,034 million in Q4 FY26

EBITDA de-grew by 19% to ₹ 510 million in Q1 FY27 as against ₹ 632 million in Q4 FY26 on sequential basis

PAT decreased to ₹ 386 million in Q1 FY27 from ₹ 453 million in Q4 FY26, de-growth of 15% on q-o-q basis

Notes:
1. On Consolidated Basis
2. PAT is before minority
3. Ind AS adjustments are carried out on account of commission, discount. And provision for sales return

Human Nutrition

-7%

Q1 FY27	Q1 FY26
1,139	1,221

(₹ in Million)



Commentary:

- The human nutrition segment contributed around 60% during the quarter to the total revenue from operations
- This segment de-grew by 7% during the quarter from ₹ 1,221 million in Q1 FY26 to ₹ 1,139 million in Q1 FY27 and it de-grew by 11% on sequential basis



Notes:
All the decimals are rounded off to their relevant nearest number

Animal Nutrition

-3%

Q1 FY27	Q1 FY26
252	260





Commentary:

- The animal nutrition segment contributed around 13% during the quarter to the total revenue from operations
- This segment de-grew by 3% during the quarter from ₹ 260 million in Q1 FY26 to ₹ 252 million in Q1 FY27 and it grew by 1% on sequential basis



Notes:
All the decimals are rounded off to their relevant nearest number

Industrial Bio-processing

+30%

Q1 FY27	Q1 FY26
306	236

(₹ in Million)



Food
14%
Q1 FY27: ₹ 263 Mn

Non-Food
2%
Q1 FY27: ₹ 43 Mn

Commentary:

- The Industrial Bio-Processing segment contributed around 16% during the quarter to the total revenue from operations
- This segment grew by 30% on y-o-y basis to ₹ 306 million in Q1 FY27 from ₹ 236 million in Q1 FY26 and on q-o-q basis it de-grew by 5%
- In this segment, food business grew by 51% to ₹ 263 million on y-o-y basis during Q1 FY27 and de-grew 5% on sequential basis. The Non-Food business stood at ₹ 43 million during the quarter and it de-grew by 30% on y-o-y basis and 8% on sequential basis



Notes:
All the decimals are rounded off to their relevant nearest number

Specialized Manufacturing

+41%

Q1 FY27	Q1 FY26
200	142

(₹ in Million)



Commentary:

- This segment contributed about 11% during the quarter to the total revenue from operations
- This segment outperformed by 41% on y-o-y basis at ₹ 200 million in Q1 FY27, and 11% on q-o-q basis



Notes:
All the decimals are rounded off to their relevant nearest number

Geographical performance

(₹ in Million)

India	49%	Q1 FY27	937	Q1 FY26	979	-4%
Americas	29%	Q1 FY27	546	Q1 FY26	565	-3%
Europe	7%	Q1 FY27	132	Q1 FY26	92	+44%
Asia*	13%	Q1 FY27	242	Q1 FY26	177	+37%
Rest of the World	2%	Q1 FY27	40	Q1 FY26	47	-15%

Notes:
1. All the decimals are rounded off to their relevant nearest number
2. *Asia is excluding India

Profit & Loss (Consolidated) – Q1 FY27

(₹ in Million)

Particulars	Q1 FY27 Un-Audited	Q4 FY26 Audited	Q1 FY26 Un-Audited	Y-o-Y (%)	Q-o-Q (%)	FY26 Audited	FY25 Audited	Y-o-Y (%)
Income from Operations	**1,898**	2,034	1,859	+2%	-7%	7,458	6,369	+17%
Expenses	**1,487**	1,503	1,391	+7%	-1%	5,568	4,790	+16%
Profit from Operations before Other Income, Finance Costs and Exceptional Item	**411**	530	468	-12%	-23%	1,890	1,579	+20%
Other Income	**130**	72	89	+47%	+80%	348	330	+5%
Profit from ordinary activities before Finance Costs and Exceptional Item	**541**	603	557	-3%	-10%	2,238	1,909	+17%
Finance costs	**6**	6	8	-24%	+1%	26	36	-26%
Profit from ordinary activities before exceptional items and tax	**535**	597	549	-3%	-10%	2,212	1,874	+18%
Exceptional item	**-**	(1)	-	-	-	(114)	-	-
Profit from ordinary activities before tax	**535**	598	549	-3%	-10%	2,325	1,874	+24%
Tax	**149**	146	145	+3%	+3%	589	534	+10%
Net Profit for the period	**386**	453	404	-5%	-15%	1,736	1,340	+30%
Earnings Per Share	**3.31**	3.84	3.57	-7%	-14%	15.08	11.72	+29%

*Notes:
On Consolidated Basis
PAT is before minority
Ind AS adjustments are carried out on account of commission, discount. and provision for sales return
All the decimals are rounded off to their relevant nearest number

Result summary - FY26 (Consolidated) Y-o-Y

Revenue (₹ mn)

17% GROWTH



EBITDA (₹ mn)

18% GROWTH



PAT (₹ mn)

30% GROWTH



Human HC +15%		Animal HC +25%		Bio Processing +16%		Specialized Manufacturing +23%	
FY26	FY25	FY26	FY25	FY26	FY25	FY26	FY25
4,674	4,035	946	760	1,176	1,018	662	539

*Notes:
1. On Consolidated Basis
2. PAT is before minority
3. Ind AS adjustments are carried out on account of commission, discount. and provision for sales return
4. All the decimals are rounded off to their relevant nearest number

Revenue Split – FY25 vs. FY26

FY25





FY26





Strong Financial Performance – FY26









*Notes:
On Consolidated Basis
PAT is before minority
Ind AS adjustments are carried out on account of commission, discount. and provision for sales return
All the decimals are rounded off to their relevant nearest number

Strong Financial Performance – FY26









Note: All the numbers are as per IndAs
All numbers are on Consolidated basis
Net working capital days =((Trade receivables + inventories – Trade payablesW)/ Revenue from operations)*365
Net Debt = Long term debt + short term debt + current maturities of long term debt – Cash & Cash Equivalent
ROE = Profit after tax / Average shareholder equity; RoCE = (Net Profit before Tax , Exceptional and extraordinary items + Finance cost) / Average (Net debt + Networth)

Balance Sheet (Consolidated)

(₹ in Million)

Particulars	FY26 Audited	FY25 Audited	FY24 Audited	FY23 Audited	FY22 Audited
Assets					
Property, plant and equipment	**2,758**	2,929	2,765	2,732	2,622
Capital work-in-progress	**512**	217	411	215	151
Intangible assets	**469**	523	479	550	609
Goodwill	**3,695**	3,334	3,253	3,209	2,961
Other non-current assets	**518**	411	350	291	289
Current assets	**10,436**	8,799	8,098	7,221	6,044
Total Assets	**18,388**	**16,213**	**15,356**	**14,218**	**12,676**
Equity And Liabilities					
Equity share capital	**224**	224	224	224	224
Other equity	**16,096**	13,985	13,018	12,127	10,662
Non-controlling interest	**512**	478	470	491	518
Non-current liabilities	**489**	564	580	601	668
Current liabilities	**1,067**	962	1,064	775	604
Total – Equity and Liabilities	**18,388**	**16,213**	**15,356**	**14,218**	**12,676**

*Notes:
On Consolidated Basis
All the decimals are rounded off to their relevant nearest number

Annexure

Company Overview

Advanced Enzymes is a research driven company with global leadership in the manufacturing of enzymes and probiotics. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, speciality applications, textile processing and others. Our aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions.

Mission

It is our mission to see that every human being is able to take advantage of the power of enzymes and probiotics for well-being and leading a healthy life!

Vision

Our vision at Advanced Enzymes is to become the largest, enzyme and probiotic -based, value provider to consumers and processors globally!

What are Probiotics?

Probiotics are live microorganisms, when administered in sufficient amount, confer health benefits to human and animals. Probiotics have now become an integral part of several therapies for the digestive disorders and newer applications for treatment of several other diseases are being developed. Probiotics act by fighting with the disease causing microorganisms and by secreting beneficial metabolites in the human/animal system.

Advanced Enzymes has developed and upscaled technologies for the production and application of several important probiotics.

What are enzymes?

Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions.
Advanced uses enzymes to replace chemicals in, and improve efficiency of, a wide variety of industrial processes for its customers.

Advanced Enzyme Technologies Limited – A Rising Global Star

advanced enzymes
Where ENZYME is Life

9
Manufacturing Units
India - 8 | USA - 1

7
R&D Units
India – 5 | USA – 1 | Germany –1

1st
Indian enzyme company

2nd
Highest market share in India

2nd
Listed integrated enzyme player globally

68+
Enzymes & Probiotics

400+
Proprietary Products

700+
Customers Worldwide

45+
Countries Worldwide Presence

750+
Employees

30+
Years of Fermentation Experience

500
m3 Fermentation Capacity

15*
Patents

17#
Food Enzyme Dossiers filed with EFSA

10**
GRAS Dossier evaluated by US FDA

1##
Novel Food Dossier filed with EFSA

Note: Facts & Figures as on 31st March, 2026
* Patents includes the filed applications
#Food Dossier filed with EFSA, out of which positive R&D opinion is received for 13 Dossiers & 4 are under evaluation
**No question letter received for 7 Dossier, 2 is self affirmed and another 1 is under evaluation
Novel food dossier has been filed with EFSA is under evaluation
All the numbers are as per IndAs
Source: Freedonia

Brief History and Evolution

1989
Incorporated as Advanced Biochemicals Pvt Ltd.

1994
1st fermentation facility commissioned at Sinnar, Maharashtra

2001
R&D locations (Thane and Sinnar) recognized by DSIR

2004
Advanced Biochemicals ranked as the largest domestic manufacturer of Industrial Enzymes. Advanced Biochemicals files its first patent

2005
Advanced Biochemicals Ltd. is renamed as Advanced Enzyme Technologies Limited

2011
Takeover of Cal-India Foods International – USA presence

2012
- Equity investment by Kotak Private Equity
- Takeover of Advanced Supplementary Technologies
- 2nd fermentation facility commissioned at Pithampur, Indore

2014
1st food enzyme Dossier as filed

2016
- Floated IPO
- Acquired 70% stake in JC Biotech with a fermentation facility at Ongole, Andhra Pradesh

2017
Acquired 100% stake in evoxx technologies GmbH, Germany
1st GRAS dossier was filed with USFDA

2018
- 4 food enzymes got approved as a processing aid with Food Safety Standard Authority of India (FSSAI)
- 4 enzymes are registered with REACH -ECHA (European Chemical Agency)

2021
Acquired 51% stake in SciTech Specialities with 2 manufacturing facilities and 1 R&D unit

2022
- Received NIH grant for ImmunoSEB and ProbioSEB CSC3)
- Approvals of 2 GRAS Dossiers for SEBtilis™ and SEBclausii™
- Increased 15% stake in JC Biotech

2023
- Acquired 50% stake in SaiGanesh Enzytech Solutions
- Acquired an additional stake of 4.83% in J C Biotech
- Launched an Wellfa, an in-house B2C consumer brand

2024
- Received approval for 2 food enzyme dossiers from EFSA
- Received no question letter for 2 GRAS dossiers from USFDA
- Increased 5.89% stake in JC Biotech

2025
- Established Starya labs for independent testing of enzymes & probiotics
- Successfully commissioned 510kW solar power plant

2026
- Three new patents filed
- Three GRAS dossiers filed with the USFDA
- Incorporation of Advanced Nutrazyme Private Limited (ANPL), expanding the Company's presence in the nutrition and wellness segment

Board of Directors

Mr. Vasant Rathi
Promoter Chairman
and Non-Executive Director

Mr. Mukund Kabra
Whole-time Director

Mr. Pramod Kasat
Independent Director

Ms. Rasika Rathi
Non-Executive Director

Mr. Vinod Jajoo
Independent Director

Mr. Sunny Sharma
Non-Executive Director

Ms. Rajshree Patel
Independent Director
(Upto June 11, 2026)

Mr. Nitin Deshmukh
Independent Director

Ms. Vandana Tilak
Independent Director

Mr. Pradip Shah
Independent Director
(Effective from June 12, 2026)

Management Team

Mr. Beni Prasad Rauka
Group - Chief Financial Officer

Mr. Harshad Doshi
CFO & COO – Advanced Enzymes, USA

Ms. Rasika Rathi
General Counsel / Vice President And Secretary – Advanced Enzymes, USA

Ms. Martina Doering
Managing Director / Head Of Business Development
evoxx Technologies, Germany

Mr. Michael Puls
Managing Director /Head Of Research and Development
evoxx Technologies, Germany

Mr. Sanjay Basantani
Company Secretary & Head Legal

How Big is the Opportunity?

Global Probiotics Market

Grow at a
CAGR 14.12%
CY 2024-29



Global Enzymes Market

Grow at a
CAGR 7.80%
till 2029

$16 Bn



	Competitive Scenario in the Global Enzymes and Probiotics Markets
Pharmaceutical	Anthem Biosciences
Nutraceutical	Novonesis, DSM, Archer Daniel Midland
Probiotics	Danone, Yakult, Novonesis, Sabinsa, Kerry, Lallemand, Unique Biotech
Bio-Catalysis	Codexis, Cambrex, Sigma-Aldrich, Lonza, Biosyntia, BASF SE, Amano Enzymes and other regional players
Animal Nutrition	Novonesis, DSM, Kemin, Novus, Alltech, Cargill, BASF SE, Biomin
Bio-Processing	Food: AB Enzymes, DSM, Novonesis, Kerry Foods Non-Food: Novonesis, DuPont, DSM, AB Enzymes, Amano Enzymes

What we are Aiming in the Opportunity?

Focus Area	Opportunity Size	Addressable market for AETL over next 5 years**	CARG(%) over next 5 years	AETL's Current Share of Revenue FY26	FY25
Human Nutrition					
Pharma/API	$ 80 mn	$ 50 mn	6%	$ 24.90 mn, 29%	$ 18.04 mn, 24%
Probiotics	$13 bn	$250 mn	14%	$ 2.4 mn, 3%	$ 4.3 mn, 6%
Bio-catalysis	$316 mn	$60 mn	6%	$ 2.8 mn, 3%	$ 2.1 mn, 3%
Nutrition	$200 mn	$200 mn	8%	$22.78 mn, 27%	$23.45 mn, 31%
Animal Nutrition	$ 2 bn	$800 mn	8%	$ 10.7 mn, 13%	$ 9.0 mn, 12%
Bio-Processing					
Food	$1.1 bn	$385 mn	7%	$10.95 mn, 13%	$9.57 mn, 13%
Non-Food	$400 mn	$100 mn	7%	$2.4 mn, 3%	$2.5 mn, 3%
Specialized Manufacturing	-	$100 mn	8%	$7.5 mn, 9%	$6.4 mn, 8%

**Opportunity size and the addressable market are as per Company's own estimates
*As of now we are considering the India only opportunity for Bio-catalysis

What Makes AETL a Unique Investment Case?

- Strong Research & Development Capabilities
- Inherent Diversification in the Business Model
- Strong Financial Performance
- Specialized Business with High Entry Barriers
- Integrated Player with Presence Across the Enzyme Value Chain
- Significant Focus on International Markets & Brand Building

Integrated Player with Presence Across the Enzyme Value Chain



Specialized Business With High Entry Barriers

Technocrat Promoters
Cumulative experience of 7+ decades in the global enzyme industry

Sustained Research & Development
Consistent Investment into R&D over the past 15+ years

Manufacturing Expertise
Specialized technical expertise in microbial fermentation developed over the last 25+ years

Proven Enzyme Development Capabilities
Proven Expertise in Successfully Developing Enzymes; Journey from only 7 in 1994 to 68+ today

Global Competitiveness
Amongst the Lowest Cost Manufacturers in the World (Benchmarked both in terms of Capex & Opex)

Diverse Product Range & Customer Base
400+ Products, 700+ Customers Worldwide

Credible Market Presence
Presence of more than 3 decades in the industry with prolonged & dedicated "enzyme" focus

Invaluable Experience & Customer Insights
Decades of Experience in Solving Customer Problems, and Invaluable Product & Process Insights

Future Growth Drivers

Continued Investment in R&D

- Identify Product gaps and Develop new Enzymes, Probiotics & Solutions thereof
- Expand Competencies in Enzymes & Probiotics, Discovery and Genetic Engineering

Broaden & Deepen Geographical Presence

- Increased focus on high return applications where AETL has strategic advantages
- Build Strategic Partnerships in Key Markets for Focus Segments

Inorganic Expansion

- Acquisition of Key Technologies, Competencies & Skill-sets which Enable Consolidation and/or Entry into New Market Segments
- Acquisition of Client Relationships & Businesses in Key Focus Markets

Focus Areas Going Ahead

Animal Nutrition

- Continuing conduct trials and studies to bring newer and effective nutritional products, which may improve the efficacy of animal feeds
- Registering and introducing more products in the domestic as well as in the international markets.
- Expand its sales and marketing team in USA, MENA and Asian market
- Targeting to strengthen the geographical reach and distribution network by appointing more distributors in the overseas markets

Bio-Catalysis

- Developing bio catalysis for API manufacturers, providing enzymatic based solutions that are target specific, helping them to save cost of energy, time and use of chemicals
- Couple of products are under the advanced stage of trials at plant level by the API manufacturers
- This is one of the opportunities, where your Company will continue its efforts and focus

Probiotics

- To introduce more probiotics products in Human Nutrition for the immunity development, active health food, gut health and various nutraceutical applications
- To launch more products on immunity development, digestion improvement, and increase nutritional level of feed in the Animal Nutrition

Baking

- In Bio-processing division, our focus is on Baking Solutions
- We have got positive response for the products in terms of efficacy and performance
- Confident to expand in Europe, Americas and Rest of World to tap the available opportunities by offering a value based approach in the Baking Industry

Shareholders Information

Stock Data

Market Capitalization (₹)	34,433 mn
Shares Outstanding	111.98 mn
Symbol (NSE/ BSE)	ADVENZYMES / 540025

Source: NSE

Stock Chart

Source: NSE

Top Institutional Holders

Institutions	OS(%)
ORBIMED ASIA III MAURITIUS	12.07
NALANDA INDIA EQUITY FUND	8.45
POLUNIN CAPITAL	2.58
CLARUS CAPITAL I	2.28
MARVAL CAPITAL	1.79
UTI MF	0.89
ICICI PRUDENTIAL MF	0.72

Shareholding Pattern



Note: Data mentioned on this slide is as on 30th June 2026

THANK YOU

Advanced Enzyme Technologies Limited
Address: 5th Floor, 'A' wing,
Sun Magnetica LIC Service Road,
Louiswadi, Thane (W) 400 604, India
Tel: +91-22-4170 3200
Fax: + 91-22-25835159
Web: www.advancedenzymes.com
CIN No: L24200MH1989PLC051018

Contact:
Mr. Ronak Saraf
Manager – Investor Relations
ir@advancedenzymes.com